Insect cell technology is a versatile and robust vaccine manufacturing platform.

Area of Science:

• Biotechnology
• Vaccinology
• Molecular Biology

Background:

• Baculovirus and insect cell culture were primarily used for research protein expression.
• The resurgence of vaccine development and regulatory acceptance of recombinant DNA technology have expanded their use.
• This technology is crucial for subunit vaccines, including virus-like particles.

Purpose of the Study:

• To review the application of baculovirus expression systems in vaccine development.
• To highlight the regulatory acceptance and market success of insect cell-derived vaccines.
• To discuss the potential of baculovirus as a platform for vectored vaccines.

Main Methods:

• Review of clinical trials and market authorizations for baculovirus-derived vaccines.
• Analysis of baculovirus as a delivery system for foreign antigens.
• Discussion of systemic and mucosal immune responses mediated by recombinant baculovirus.

Main Results:

• Demonstrated product quality, safety, and efficacy in numerous clinical trials for candidate vaccines.
• Market authorization of Cervarix (HPV vaccine) as a milestone for regulatory acceptance.
• Established insect cell technology as a dominant platform for veterinary vaccines.

Conclusions:

• Baculovirus expression systems are increasingly adopted for human and veterinary vaccine development.
• Regulatory acceptance has paved the way for more baculovirus-derived vaccine approvals.
• Recombinant baculovirus shows promise as vectored vaccines for inducing robust immune responses.